|
PERTH, Australia, March 17, 2026 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end Contract Development and Manufacturing Organisation (CDMO) announced it has initiated a comprehensive CMC (Chemistry, Manufacturing, and Controls) program for the advancement of RLS-2201, a proprietary injectable formulation of Quetiapine being developed by Patrys Ltd (ASX: PAB) for the acute treatment of delirium in intensive care settings.
A reformulated RLS-2201 is being produced at BioCina's sterile manufacturing facility in Perth, under conditions designed to confirm the reproducibility and robustness of the manufacturing process. The reformulated RLS-2201 will support ICH-aligned stability studies required for regulatory submission and provide early supply for Patrys' planned first-in-human clinical activities.
"We are proud to be advancing RLS-2201 alongside a world-class CDMO partner whose deep manufacturing expertise and technical capabilities are proving instrumental in de-risking this program. Their collaborative approach to regulatory engagement gives us strong confidence as we move toward clinical trials. Together, we believe RLS-2201 has the potential to address a critical unmet need in the treatment of delirium in acute hospital settings," said Dr. Samantha South, CEO, Patrys.
The initiation of CMC activities represents a significant de-risking step for the RLS-2201 program. By validating the manufacturing process for clinical readiness at this stage, Patrys and BioCina are establishing a technically sound and regulatorily defensible pathway toward clinical trial entry, targeted for the second half of 2026. This engagement further strengthens BioCina's partnership with Patrys, reflecting BioCina's commitment to supporting clients at every stage of their product development journey.
"We are thrilled to support Patrys' journey for RLS-2201. BioCina's 50 years of experience in the development and manufacturing of sterile injectables is more than just a capability. We ensure partners like Patrys can progress to clinic with confidence, and keep the focus where it belongs - improving patient outcomes," said Dr. Tommy Broudy, CEO, BioCina.
About BioCina
BioCina is a global end-to-end Contract Development and Manufacturing Organisation (CDMO) with over 50 years of sterile Drug Product manufacturing experience, serving clients across the U.S., Europe, and Asia Pacific. With facilities recognised by the US FDA, EMA, TGA, and other key regulatory authorities, BioCina delivers Drug Substance and Drug Product solutions from early development through to commercial scale.
BioCina's capabilities span sterile injectable manufacturing of small and large molecule products in multiple formats, as well as microbial biologics, pDNA, mRNA and LNP-based modalities. Partnering with BioCina in Australia provides clients with access to one of the world's most attractive R&D tax incentive programs, offering a meaningful cost advantage throughout development and manufacture.
For more information, visit www.biocina.com
About Patrys
Based in Perth, Australia, Patrys, (ASX: PAB), is a clinical-stage biotechnology company advancing a dual-platform strategy combining innovative antibody therapeutics with a near-term CNS pharmaceutical program. Patrys' deoxymab platform comprises novel cell-penetrating antibodies targeting intracellular disease mechanisms with a focus on immune-mediated inflammatory and other high-unmet-need indications.
Patrys' CNS program, RLS-2201, is a proprietary injectable reformulation of quetiapine for the treatment of delirium in intensive, aged and palliative care setting, advancing via the FDA 505(b)(2) regulatory pathway. Together, these platforms position Patrys as a catalyst-rich, balanced development company, combining a de-risked reformulation asset with longer-term biologics innovation.
For more information, visit www.patrys.com
Media Contact
media@biocina.com
Photo - https://mma.prnasia.com/media2/2933870/patrys_release_image_250225_8335.jpg?p=medium600
Logo - https://mma.prnasia.com/media2/2346937/BioCina_New_Logo.jpg?p=medium600
PERTH, Australia, March 17, 2026 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end Contract Development and Manufacturing Organisation (CDMO) announced it has initiated a comprehensive CMC (Chemistry, Manufacturing, and Controls) program for the advancement of RLS-2201, a proprietary injectable formulation of Quetiapine being developed by Patrys Ltd (ASX: PAB) for the acute treatment of delirium in intensive care settings.
A reformulated RLS-2201 is being produced at BioCina's sterile manufacturing facility in Perth, under conditions designed to confirm the reproducibility and robustness of the manufacturing process. The reformulated RLS-2201 will support ICH-aligned stability studies required for regulatory submission and provide early supply for Patrys' planned first-in-human clinical activities.
"We are proud to be advancing RLS-2201 alongside a world-class CDMO partner whose deep manufacturing expertise and technical capabilities are proving instrumental in de-risking this program. Their collaborative approach to regulatory engagement gives us strong confidence as we move toward clinical trials. Together, we believe RLS-2201 has the potential to address a critical unmet need in the treatment of delirium in acute hospital settings," said Dr. Samantha South, CEO, Patrys.
The initiation of CMC activities represents a significant de-risking step for the RLS-2201 program. By validating the manufacturing process for clinical readiness at this stage, Patrys and BioCina are establishing a technically sound and regulatorily defensible pathway toward clinical trial entry, targeted for the second half of 2026. This engagement further strengthens BioCina's partnership with Patrys, reflecting BioCina's commitment to supporting clients at every stage of their product development journey.
"We are thrilled to support Patrys' journey for RLS-2201. BioCina's 50 years of experience in the development and manufacturing of sterile injectables is more than just a capability. We ensure partners like Patrys can progress to clinic with confidence, and keep the focus where it belongs - improving patient outcomes," said Dr. Tommy Broudy, CEO, BioCina.
About BioCina
BioCina is a global end-to-end Contract Development and Manufacturing Organisation (CDMO) with over 50 years of sterile Drug Product manufacturing experience, serving clients across the U.S., Europe, and Asia Pacific. With facilities recognised by the US FDA, EMA, TGA, and other key regulatory authorities, BioCina delivers Drug Substance and Drug Product solutions from early development through to commercial scale.
BioCina's capabilities span sterile injectable manufacturing of small and large molecule products in multiple formats, as well as microbial biologics, pDNA, mRNA and LNP-based modalities. Partnering with BioCina in Australia provides clients with access to one of the world's most attractive R&D tax incentive programs, offering a meaningful cost advantage throughout development and manufacture.
For more information, visit www.biocina.com
About Patrys
Based in Perth, Australia, Patrys, (ASX: PAB), is a clinical-stage biotechnology company advancing a dual-platform strategy combining innovative antibody therapeutics with a near-term CNS pharmaceutical program. Patrys' deoxymab platform comprises novel cell-penetrating antibodies targeting intracellular disease mechanisms with a focus on immune-mediated inflammatory and other high-unmet-need indications.
Patrys' CNS program, RLS-2201, is a proprietary injectable reformulation of quetiapine for the treatment of delirium in intensive, aged and palliative care setting, advancing via the FDA 505(b)(2) regulatory pathway. Together, these platforms position Patrys as a catalyst-rich, balanced development company, combining a de-risked reformulation asset with longer-term biologics innovation.
For more information, visit www.patrys.com
Media Contact
media@biocina.com
Photo - https://mma.prnasia.com/media2/2933870/patrys_release_image_250225_8335.jpg?p=medium600
Logo - https://mma.prnasia.com/media2/2346937/BioCina_New_Logo.jpg?p=medium600
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
BioCina Initiates Comprehensive Manufacturing Program for Patrys' Proprietary Injectable Therapeutic to Alleviate Delirium
|
PARIS, March 17, 2026 /PRNewswire/ -- Le Clarence, an essential address of Parisian haute gastronomy, celebrates its two stars in the Michelin Guide at the 2026 ceremony. This distinction honors the work and vision of Andrea Capasso, Executive Chef since September 2025, who achieves, in his very first year at the helm of the kitchen, a major recognition of his rigor and culinary sensitivity.
To view the Multimedia News Release, please click:
https://www.multivu.com/domaine-clarence-dillon/9387451-en-le-clarence-awarded-two-michelin-stars-under-direction-andrea-capasso
Located just steps from the Grand Palais, in a setting that is both majestic and intimate, Le Clarence was opened in November 2015 at the initiative of the family-owned group Domaine Clarence Dillon, owner of prestigious wine estates including the legendary Château Haut-Brion. This address embodies a refined and timeless French art de vivre, championed by H.R.H. Prince Robert of Luxembourg, representing the fourth generation of the family and serving as President of the company.
A distinction honoring Andrea Capasso's cuisine
In his early thirties, with fourteen years of experience already behind him, Andrea Capasso brings to Le Clarence an energy that is both serene and vibrant. Having been part of the restaurant for seven years, he now embodies both its continuity and momentum. His cuisine goes beyond technical mastery, it is something to be felt. Conceived as an enveloping and electrifying score unfolding in sequences, his culinary writing explores the essence of carefully selected ingredients, worked with precision and then elevated to reveal multiple expressions, sometimes unexpected, always clear. A guiding thread of enveloping delicacy and fine acidity extends each bite, while the land-and-sea pairings so dear to Le Clarence take on a new dimension. Andrea Capasso cooks to move and restore through emotion, a sincere approach that leaves guests with a lasting desire to return.
"Receiving two Michelin stars in my first year as Executive Chef is an immense honor," says Andrea Capasso. "This distinction above all recognizes a collective effort, the daily commitment of those who bring Le Clarence to life, and the trust that has been placed in me. It encourages us to continue cooking from the heart, to seek genuine emotion, and to offer each guest a moment of pleasure that remains in their memory."
Born from observing the preferences of his guests, Andrea Capasso has introduced, alongside the tasting menus, a weekday lunch menu that evolves with the seasons. Designed for busy schedules, it offers the chance to experience Le Clarence in just one hour, without compromising on taste or standards. A feat in which the precision of the service rivals the creativity on the plate.
An experience elevated by excellence in service
At the heart of this experience, Charles Weyland orchestrates an elegant yet relaxed hospitality. Trained at leading establishments, he brings to Le Clarence a vision of service rooted in attentive listening and an intuitive understanding of each guest. Far from any formality, he creates a warm and almost intimate atmosphere, where kitchen and dining room engage in perfect harmony, enhancing every moment spent within the private mansion.
Le Clarence also draws on one of the most remarkable wine cellars in Paris, bringing together nearly 2,000 references from the finest French terroirs. Each wine service, orchestrated by the sommelier team, becomes a moment of distinction: personalised guidance, decanting and food-and-wine pairings create a unique dialogue between gastronomy and grands crus, enhancing every dish and every moment spent at the restaurant.
With the consecration of its two Michelin stars, Le Clarence affirms the singularity of Andrea Capasso's cuisine and the excellence of a holistic experience, establishing itself, more than ever, among Paris's greatest gastronomic destinations.
About Domaine Clarence Dillon
Founded in 1935, the family-owned group Domaine Clarence Dillon brings together some of the most prestigious wine estates in the world: Château Haut-Brion, Château La Mission Haut-Brion, Château Quintus, Clarendelle and Klara. Since 2015, Domaine Clarence Dillon has also established a Parisian residence, a true ambassador of the French art de vivre cherished by Prince Robert of Luxembourg, President of Domaine Clarence Dillon and representative of the fourth generation of the family. It is home to the double Michelin-starred restaurant Le Clarence and La Cave du Château, an exceptional boutique dedicated to the finest wines and spirits of the French terroir, also present in Bordeaux (https://www.lacaveduchateau.com).
Since 2018, Prince Robert of Luxembourg and Domaine Clarence Dillon have been members of Primum Familiae Vini, an international association of 12 families whose châteaux and estates produce some of the world's greatest wines. Domaine Clarence Dillon also continues the philanthropic tradition dear to its founder by supporting the Grand Palais, located opposite its private mansion. Since 2023, the group's wines have been official partners of the Academy Museum of Motion Pictures and are exclusively served at the Oscars® ceremony.
Media Contacts:
Klante flore@klante.co
PARIS, March 17, 2026 /PRNewswire/ -- Le Clarence, an essential address of Parisian haute gastronomy, celebrates its two stars in the Michelin Guide at the 2026 ceremony. This distinction honors the work and vision of Andrea Capasso, Executive Chef since September 2025, who achieves, in his very first year at the helm of the kitchen, a major recognition of his rigor and culinary sensitivity.
To view the Multimedia News Release, please click:
https://www.multivu.com/domaine-clarence-dillon/9387451-en-le-clarence-awarded-two-michelin-stars-under-direction-andrea-capasso
Located just steps from the Grand Palais, in a setting that is both majestic and intimate, Le Clarence was opened in November 2015 at the initiative of the family-owned group Domaine Clarence Dillon, owner of prestigious wine estates including the legendary Château Haut-Brion. This address embodies a refined and timeless French art de vivre, championed by H.R.H. Prince Robert of Luxembourg, representing the fourth generation of the family and serving as President of the company.
A distinction honoring Andrea Capasso's cuisine
In his early thirties, with fourteen years of experience already behind him, Andrea Capasso brings to Le Clarence an energy that is both serene and vibrant. Having been part of the restaurant for seven years, he now embodies both its continuity and momentum. His cuisine goes beyond technical mastery, it is something to be felt. Conceived as an enveloping and electrifying score unfolding in sequences, his culinary writing explores the essence of carefully selected ingredients, worked with precision and then elevated to reveal multiple expressions, sometimes unexpected, always clear. A guiding thread of enveloping delicacy and fine acidity extends each bite, while the land-and-sea pairings so dear to Le Clarence take on a new dimension. Andrea Capasso cooks to move and restore through emotion, a sincere approach that leaves guests with a lasting desire to return.
"Receiving two Michelin stars in my first year as Executive Chef is an immense honor," says Andrea Capasso. "This distinction above all recognizes a collective effort, the daily commitment of those who bring Le Clarence to life, and the trust that has been placed in me. It encourages us to continue cooking from the heart, to seek genuine emotion, and to offer each guest a moment of pleasure that remains in their memory."
Born from observing the preferences of his guests, Andrea Capasso has introduced, alongside the tasting menus, a weekday lunch menu that evolves with the seasons. Designed for busy schedules, it offers the chance to experience Le Clarence in just one hour, without compromising on taste or standards. A feat in which the precision of the service rivals the creativity on the plate.
An experience elevated by excellence in service
At the heart of this experience, Charles Weyland orchestrates an elegant yet relaxed hospitality. Trained at leading establishments, he brings to Le Clarence a vision of service rooted in attentive listening and an intuitive understanding of each guest. Far from any formality, he creates a warm and almost intimate atmosphere, where kitchen and dining room engage in perfect harmony, enhancing every moment spent within the private mansion.
Le Clarence also draws on one of the most remarkable wine cellars in Paris, bringing together nearly 2,000 references from the finest French terroirs. Each wine service, orchestrated by the sommelier team, becomes a moment of distinction: personalised guidance, decanting and food-and-wine pairings create a unique dialogue between gastronomy and grands crus, enhancing every dish and every moment spent at the restaurant.
With the consecration of its two Michelin stars, Le Clarence affirms the singularity of Andrea Capasso's cuisine and the excellence of a holistic experience, establishing itself, more than ever, among Paris's greatest gastronomic destinations.
About Domaine Clarence Dillon
Founded in 1935, the family-owned group Domaine Clarence Dillon brings together some of the most prestigious wine estates in the world: Château Haut-Brion, Château La Mission Haut-Brion, Château Quintus, Clarendelle and Klara. Since 2015, Domaine Clarence Dillon has also established a Parisian residence, a true ambassador of the French art de vivre cherished by Prince Robert of Luxembourg, President of Domaine Clarence Dillon and representative of the fourth generation of the family. It is home to the double Michelin-starred restaurant Le Clarence and La Cave du Château, an exceptional boutique dedicated to the finest wines and spirits of the French terroir, also present in Bordeaux (https://www.lacaveduchateau.com).
Since 2018, Prince Robert of Luxembourg and Domaine Clarence Dillon have been members of Primum Familiae Vini, an international association of 12 families whose châteaux and estates produce some of the world's greatest wines. Domaine Clarence Dillon also continues the philanthropic tradition dear to its founder by supporting the Grand Palais, located opposite its private mansion. Since 2023, the group's wines have been official partners of the Academy Museum of Motion Pictures and are exclusively served at the Oscars® ceremony.
Media Contacts:
Klante flore@klante.co
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Le Clarence Awarded Two Michelin Stars Under the Direction of Andrea Capasso
